Core Viewpoint - Jiangsu Shuoshi Biotechnology Co., Ltd. has received a medical device registration certificate for in vitro diagnostic reagents, which is expected to enhance its product variety and competitive edge in the market [1]. Group 1: Medical Device Registration Certificate - The company has obtained a medical device registration certificate issued by the National Medical Products Administration for in vitro diagnostic reagents [1]. - This registration expands the company's product offerings and strengthens its presence in the in vitro diagnostics sector [1]. Group 2: Impact on the Company - The acquisition of the medical device registration certificate is anticipated to meet diverse clinical needs and enhance the company's overall competitiveness [1]. - It is expected to improve the company's market expansion capabilities [1].

Group 1 - The company has received a medical device registration certificate for in vitro diagnostic reagents from the Shanghai Municipal Drug Administration [1] - The acquisition of this new product registration enriches the company's product line and is expected to have a positive impact on business development [1] - The company is currently unable to predict the future revenue impact of the new products and advises investors to pay attention to investment risks [1]

Group 1: Convertible Bond Information - The company issued 7.38 million convertible bonds with a total amount of 738 million yuan, and the bonds began trading on August 20, 2020 [2] - The initial conversion price was set at 21.50 yuan per share, with the conversion period from February 3, 2021, to July 27, 2026 [3] - The conversion price has been adjusted multiple times, with the latest adjustment reducing it to 20.64 yuan per share effective from May 10, 2023 [6] Group 2: Price Adjustment Conditions - The company can propose a downward adjustment of the conversion price if the stock price closes below 90% of the current conversion price for at least 10 out of 20 consecutive trading days [7] - The company has a specific procedure for announcing any adjustments, which includes disclosing the decision in a timely manner and holding a shareholder meeting for approval [8] Group 3: Future Price Adjustment Expectations - The period for potential triggering of the price adjustment condition starts from August 11, 2025, and the company has already observed 5 trading days where the stock price closed below the 90% threshold [10] - If the conditions are met, the company will convene a board meeting to decide on the adjustment and will disclose the outcome the next trading day [10] Group 4: New Product Registration - The company has received a medical device registration certificate for in vitro diagnostic reagents from the National Medical Products Administration [11] - This new product registration is expected to enrich the company's product line and positively impact business development, although the future revenue impact remains uncertain [11]